Brief: RenovoRx Gets FDA Orphan Drug Designation For Oxaliplatin To Treat Pancreatic Cancer
28/05/2026 13:48
BRIEF-RenovoRx Gets FDA Orphan Drug Designation For Oxaliplatin To Treat Pancreatic Cancer May 28 (Reuters) - RenovoRx Inc RNXT.O:
ANNOUNCES FDA ORPHAN DRUG DESIGNATION GRANTED: OXALIPLATIN FOR THE TREATMENT OF PANCREATIC CANCER
ODD PROVIDES SEVEN YEARS OF MARKET EXCLUSIVITY UPON FDA APPROVAL
TIGER-PAC TRIAL ENROLLMENT TO CLOSE JUNE 2026, FINAL DATA READOUT MID TO LATE 2027
Source text: ID:nGNXs853c
Further company coverage: RNXT.O
((Reutersbriefs@thomsonreuters.com;))
Recent news on RenovoRx
See all newsBrief: RenovoRx Gets FDA Orphan Drug Designation For Oxaliplatin To Treat Pancreatic Cancer
RenovoRx Q1 revenue rises as number of active cancer centers increase
RenovoRx 2025 net loss widens on higher operating expenses
Brief: RenovoRx FY Net Income USD -11.168 Million
U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies